Predictive Values of Apelin for Myocardial Fibrosis in Hypertrophic Cardiomyopathy
- PMID: 31019180
- DOI: 10.1536/ihj.18-598
Predictive Values of Apelin for Myocardial Fibrosis in Hypertrophic Cardiomyopathy
Abstract
Apelin was proved to attenuate cardiac interstitial fibrosis. However, the association between apelin level and myocardial fibrosis in patients with hypertrophic cardiomyopathy (HCM) is still unclear.This study aims to determine whether apelin is associated with myocardial fibrosis in HCM and investigate the predictive values of apelin for myocardial fibrosis in HCM.One hundred sixteen patients with HCM were enrolled in this study. Plasma apelin-13 and high-sensitivity cardiac troponin I (cTNI) were measured. The cardiac systolic and diastolic functions were evaluated by echocardiography, and the presence and extent of cardiac fibrosis were assessed by cardiac magnetic resonance. All statistical data were analyzed by SPSS version 21.0.The percentage of late gadolinium enhancement (LGE) was negatively correlated with apelin and positively correlated with cTNI, maximum wall thickness (MWT), and left ventricular mass index in the overall patients with HCM and LGE. Apelin, cTNI, MWT, and left ventricular ejection fraction were independent predictors of the presence of LGE. The cutoff values of apelin, cTNI, and MWT were 1.24 pg/mL, 0.031 ng/mL, and 19 mm, respectively, for the prediction of LGE. The combined measurements of MWT ≥ 19 mm and/or apelin ≤ 1.24 pg/mL, as well as the combined measurements of MWT ≥ 19 mm and/or cTNI ≥ 0.031 ng/mL, obtained higher specificity and higher sensitivity, thus, indicating the presence of LGE.Plasma apelin and cTNI are independent predictors of myocardial fibrosis. The combined measurements of serum apelin and MWT, as well as cTNI and MWT, showed higher predictive values for predicting myocardial fibrosis in patients with HCM.
Keywords: MWT; Prediction of fibrosis in heart; cTNI.
Similar articles
-
Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy.PLoS One. 2016 Jan 14;11(1):e0146572. doi: 10.1371/journal.pone.0146572. eCollection 2016. PLoS One. 2016. PMID: 26765106 Free PMC article.
-
Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction.Sci Rep. 2021 Feb 22;11(1):4297. doi: 10.1038/s41598-021-83678-z. Sci Rep. 2021. PMID: 33619345 Free PMC article.
-
Diffusion-weighted imaging in hypertrophic cardiomyopathy: association with high T2-weighted signal intensity in addition to late gadolinium enhancement.Int J Cardiovasc Imaging. 2020 Nov;36(11):2229-2238. doi: 10.1007/s10554-020-01933-2. Epub 2020 Jul 14. Int J Cardiovasc Imaging. 2020. PMID: 32666169
-
Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.JACC Cardiovasc Imaging. 2016 Dec;9(12):1392-1402. doi: 10.1016/j.jcmg.2016.02.031. Epub 2016 Jul 20. JACC Cardiovasc Imaging. 2016. PMID: 27450876 Review.
-
Prediction of ventricular arrhythmias using cardiovascular magnetic resonance.Eur Heart J Cardiovasc Imaging. 2013 Jun;14(6):518-25. doi: 10.1093/ehjci/jes302. Epub 2013 Jan 16. Eur Heart J Cardiovasc Imaging. 2013. PMID: 23324829 Review.
Cited by
-
Clinical findings using echocardiography and plasma cardiac troponin I and pathological findings in dogs with hypertrophic cardiomyopathy: A retrospective study.Open Vet J. 2023 Jun;13(6):742-752. doi: 10.5455/OVJ.2023.v13.i6.9. Epub 2023 Jun 11. Open Vet J. 2023. PMID: 37545712 Free PMC article.
-
Endothelial cell dysfunction in cardiac disease: driver or consequence?Front Cell Dev Biol. 2023 Oct 25;11:1278166. doi: 10.3389/fcell.2023.1278166. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37965580 Free PMC article. Review.
-
The relationship between serum Lumican levels and myocardial fibrosis in patients with hypertrophic cardiomyopathy.Biomark Med. 2025 Mar;19(6):187-195. doi: 10.1080/17520363.2025.2473304. Epub 2025 Mar 3. Biomark Med. 2025. PMID: 40033847
-
Circulating Biomarkers in Hypertrophic Cardiomyopathy.J Am Heart Assoc. 2022 Dec 6;11(23):e027618. doi: 10.1161/JAHA.122.027618. Epub 2022 Nov 16. J Am Heart Assoc. 2022. PMID: 36382968 Free PMC article. Review.
-
Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond.Egypt Heart J. 2024 Dec 7;76(1):156. doi: 10.1186/s43044-024-00587-y. Egypt Heart J. 2024. PMID: 39645546 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials